Educational Breast Cancer Event Focuses on Individual Disease Types
CINCINNATISort of like snowflakes, no two breast cancers are exactly alike.
To educate on how breast cancers differ at the genetic level and how these differences lead to personalized treatment, as well as discussions on the latest in breast cancer research and explanations on how risk and recurrence can be minimized, the University of Cincinnati (UC) Cancer Institutes Breast Cancer Center is hosting a free educational event for survivors, their families and the community.
The "We See Individual Breast Cancers: You See Personalized Care breast cancer conference, being held from 9 a.m. to 3 p.m. Saturday Nov. 4, at the Kingsgate Marriott Conference Center, 151 Goodman Drive, is free and open to the public. The event will involve presentations from experts within the institute at UC, the community and beyond.
Tina Hieken, MD, associate professor of surgery at Mayo Clinic, will be the featured speaker for the day and will be presenting on the breast microbiomeexploring the impact of local bacteria and other microorganisms on breast health.
Other talks will touch on "tumor mapping, genetic profiling, targeted therapies and why certain genes make a person more susceptible to cancer.
"This year, were taking a close look into the genes and pathways that make each cancer different, says Elyse Lower, MD, director of the center, professor in the Division of Hematology Oncology at the UC College of Medicine and a UC Health oncologist. "This annual event allows us to educate attendees about new advances in personalized medicine and what our experts at the UC Cancer Institute are doing to fight this disease. Were excited to host the conference again this year to empower patients and members of the community and to showcase our strengths locally.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.